Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Pernot

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
EMBO Molecular Medicine|February 17, 2025
Repression of apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancerBéatrice Demoures, Fabienne Soulet, Jean Descarpentrie, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 studyMélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Journal for Immunotherapy of Cancer|October 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world studyEmily Alouani, Julien Taieb, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO studyIona Campo-Le-Brun, Emma Grapinet, Valerie Aurillac, et al.
Nature Medicine|April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialDevalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
EMBO Molecular Medicine|February 17, 2025
Repression of apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancerBéatrice Demoures, Fabienne Soulet, Jean Descarpentrie, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 studyMélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Journal for Immunotherapy of Cancer|October 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world studyEmily Alouani, Julien Taieb, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO studyIona Campo-Le-Brun, Emma Grapinet, Valerie Aurillac, et al.
Nature Medicine|April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialDevalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
Pageof 11